Shares of Apogee Therapeutics (APGE) are soaring 5.28% in intraday trading on Tuesday, as investors react positively to a reaffirmed Buy rating from Mizuho Securities. The surge comes after analyst Joseph Catanzaro maintained his bullish stance on the stock and set an ambitious price target of $105.00.

The Mizuho Securities report, released before the market opened, appears to have sparked renewed interest in Apogee Therapeutics. Analyst ratings and price targets often serve as key indicators for investors, potentially influencing trading decisions and stock performance.

While specific details about Apogee Therapeutics' business developments or financial performance were not provided in the available news, the maintained Buy rating and the high price target suggest that Mizuho Securities sees significant upside potential for the company. As the trading session progresses, it remains to be seen whether Apogee Therapeutics can maintain its momentum and close the day near its intraday highs.